Postoperative Immunotherapy for Esophageal Cancer
Author Information
Author(s): Xie Xihao, Zhang Hai, He Haiquan, Wu Bomeng, Chen Ying, Lin Wanli, Feng Qingyi, Chen Qunqing
Primary Institution: Gaozhou People’s Hospital Affiliated to Guangdong Medical University
Hypothesis
Does postoperative immunotherapy improve disease-free recurrence rates in esophageal squamous cell carcinoma after radical surgery?
Conclusion
Postoperative immunotherapy did not improve disease-free recurrence rates compared to chemotherapy alone for esophageal cancer patients.
Supporting Evidence
- The incidence of hypothyroidism was significantly higher in the immunotherapy group (25.0%) compared to the chemotherapy group (2.5%).
- Local recurrence rates were 17.5% in the chemotherapy group and 13.9% in the immunotherapy group.
- During the 2-year follow-up, there were no significant differences in recurrence rates between the two groups.
Takeaway
This study looked at whether adding immunotherapy after surgery helps patients with esophageal cancer. It found that it doesn't make a difference in preventing the cancer from coming back.
Methodology
This retrospective study evaluated patients who underwent radical surgery for esophageal cancer and received either chemotherapy or immunotherapy combined with chemotherapy.
Potential Biases
Potential biases due to the retrospective nature and single-center design.
Limitations
The study was a single-center retrospective analysis with a small sample size, limiting generalizability.
Participant Demographics
Patients aged 18-75 years with pathologically confirmed esophageal squamous cell carcinoma.
Statistical Information
P-Value
0.489
Confidence Interval
95% CI = 0.378–2.871
Statistical Significance
p=0.489
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website